Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: Dummy run and individual case review

Matzinger, Oscar; Poortmans, Philip; Giraud, Jean-Yves; Maingon, P.; Budiharto, Tom; Bergh, Alfons C.M. van den; Davis, J.B.; Musat, E.; Ataman, Fatma; Huyskens, D.; Gulybán, Ákos; Bolla, M.

doi:10.1016/j.radonc.2008.10.022

Cited by 51 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The medium value of 1000 proved to be the best for both algorithms. Actually there exists no clear consensus on precise constraints [20] neither unique in dose nor in volume fraction [2,6,8,11,12,20,22]. Our relatively narrow constraints, especially for the rectum, should pose a challenge for the optimising algorithms.…”

Section: Patients Materials and Methodsmentioning

confidence: 99%

IMRT of prostate cancer

Treutwein

Hipp²,

Kölbl³

et al. 2009

Strahlenther Onkol

View full text Add to dashboard Cite

Background and Purpose: Intensity-modulated radiation therapy (IMRT) has shown its superiority to 3D conformal radiotherapy in the treatment of prostate cancer. Different optimisation algorithms are available: algorithms which first optimise the fluence followed by a sequencing (IM) and algorithms which involve the machine parameters directly in the optimisation process (DSS). The aim of this treatment planning study is to compare both of them regarding dose distribution and treatment time.Patients, Material and Methods: Ten consecutive patients with localized prostate cancer were enrolled for this planning study. The planning target volume (PTV) and the rectum volume, urinary bladder and femoral heads as organs at risk (OAR) were delineated. Average doses, the target dose homogeneity H, D 5 , D 95 , monitor units per fraction and the number of segments were evaluated. Results:While there is only a small difference in the mean doses at rectum and bladder, there is a significant advantage for the target dose homogeneity in the DSS-optimised plans compared to the IMoptimised ones. Differences in the monitor units (nearly 10% less for DSS) and the number of segments are also statistically significant and reduce the treatment time. Conclusion:Particularly with regard to the tumor control probability the better homogeneity of the DSS-optimised plans is more profitable. The shorter treatment time is an improvement regarding intrafractional organ motion. The DSS-optimiser results in a higher target dose homogeneity and, simultaneously, in a lower number of monitor units. Therefore it should be preferred for IMRT of prostate cancer.

show abstract

Section: Patients Materials and Methodsmentioning

confidence: 99%

IMRT of prostate cancer

Treutwein

Hipp²,

Kölbl³

et al. 2009

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…A focused literature search conducted by NICE 112 identified three published papers from two new RCTs. 95,113 Only one paper had published full results of the trial at the time of analysis (the SPCG-7 trial 96 ). Six RCTs identified in the NICE prostate cancer guideline 71 have published additional follow-up results with findings in support of combined radiotherapy and hormone therapy.…”

Section: Case Study 1: Full Guideline Model For Prostate Cancermentioning

confidence: 99%

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Lord

Willis²,

Eatock³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

“…Standard of care for patients with early stage Hodgkin's lymphoma is currently represented by a combination of a brief chemotherapy (2-3 or 3-4 ABVD or ABVD-like cycles, respectively in favorable or unfavorable disease) followed by [30][31][32][33][34][35][36] Gy IFRT [11-13, 21-24, 32, 34, 35].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, also well known as interobserver variability in the delineation of gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV) is a problem in modern radiotherapy treatment planning [29,31,37,39,40,42,[46][47][48].…”

Section: Introductionmentioning

confidence: 99%